Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Insulin lispro

DRUG

recombinant human hyaluronidase PH20

DRUG

Insulin aspart

DRUG

Insulin glulisine

DRUG

Insulin glargine

Trial Locations (19)

20782

Medstar Research Institute, Hyattsville

33021

Center for Diabetes and Endocrine Care, Hollywood

33136

Diabetes Research Institute, Miami

48202

Henry Ford Health System, Detroit

55416

International Diabetes Center, Minneapolis

59701

Mercury Street Medical, Butte

67211

Mid-America Diabetes Associates, Wichita

70112

Tulane University Health Sciences Center, New Orleans

75390

UT Southwestern Medical Center at Dallas, Dallas

78229

Cetero Research-San Antonio, San Antonio

78681

Texas Diabetes and Endocrinology, Round Rock

80045

Barbara Davis Center for Childhood Diabetes, Aurora

83404

Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls

89052

Desert Endocrinology, Henderson

92026

AMCR Institute, Inc., Escondido

92037

Scripps Whittier Diabetes Institute, La Jolla

94401

Mills-Peninsula Health Services, San Mateo

98105

University of Washington School of Medicine, Seattle

98502

West Olympia Internal Medicine, Olympia

Sponsors
All Listed Sponsors
lead

Halozyme Therapeutics

INDUSTRY

NCT01194245 - Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus | Biotech Hunter | Biotech Hunter